Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Chronic 2 Pheochromocytoma 1 Paraganglioma 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Gastrointestinal Stromal Tumors 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 244 Carboplatin 213 Pemetrexed 179 Cisplatin 133 Paclitaxel 115 Nivolumab 102 Docetaxel 88 osimertinib 84 durvalumab 79 Specimen Handling 56 atezolizumab 55 Gemcitabine 53 Drug Therapy 53 Magnetic Resonance Spectroscopy 50 Radiosurgery 49 Radiotherapy 48 Ipilimumab 41 130-nm albumin-bound paclitaxel 39 cemiplimab 38 Bevacizumab 35 tislelizumab 31 Cetuximab 30 amivantamab 23 Taxes 22 Blood Specimen Collection 21 Platinum Compounds 20 Immunotherapy 18 Immune Checkpoint Inhibitors 18 Radiation 17 Erlotinib Hydrochloride 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × guadecitabine × 1 year × Clear all

NCT02998567 2026-05-12

HyPeR

Royal Marsden NHS Foundation Trust

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡